Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25174282 | 1.00 | BACE1 (0.33) | BACE1BACE2PRMT5WDR77USP30 | |
| SCHEMBL21058443 | 0.89 | AAK1 (0.35) | BACE1BACE2PRMT5WDR77USP30 | |
| SCHEMBL17518584 | 0.89 | BACE1 (0.34) | BACE1BACE2PRMT5WDR77USP30 | |
| SCHEMBL29363705 | 0.86 | GPR119 (0.33) | — | |
| SCHEMBL25028818 | 0.86 | GPR119 (0.33) | — | |
| SCHEMBL23330822 | 0.84 | JAK2 (0.41) | BACE1BACE2PRMT5WDR77USP30 | |
| SCHEMBL25191490 | 0.83 | JAK2 (0.32) | — | |
| SCHEMBL20689530 | 0.83 | USP30 (0.33) | PRMT5WDR77USP30BUB1 | |
| SCHEMBL28594656 | 0.82 | HTR6 (0.40) | BACE1BACE2PRMT5WDR77USP30 | |
| SCHEMBL25028819 | 0.82 | HTR6 (0.34) | BACE1BACE2PRMT5WDR77USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023064857-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | BACE1 2730/4885BACE2 3068/4885PRMT5 1329/4885 |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | BACE1 2730/4885BACE2 3068/4885PRMT5 1329/4885 |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | BACE1 2730/4885BACE2 3068/4885PRMT5 1329/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | BACE1 2730/4885BACE2 3068/4885PRMT5 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.